Clinical Trial Update: Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing twice-daily mesalazine to once-daily dosing in acute mild to moderate ulcerative colitis; completed study evaluating safety and efficacy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• SPD476

Snippet

Sponsor: Shire | Conditions: Colitis, Ulcerative | Phase 3 | Status: COMPLETED